Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 5
1991 10
1992 15
1993 18
1994 40
1995 56
1996 93
1997 112
1998 156
1999 249
2000 319
2001 384
2002 484
2003 508
2004 571
2005 657
2006 745
2007 753
2008 802
2009 806
2010 971
2011 1069
2012 1152
2013 1166
2014 1159
2015 1208
2016 1162
2017 1160
2018 1194
2019 1259
2020 1366
2021 1418
2022 1360
2023 1350
2024 1411
2025 1581
2026 145

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24,188 results

Results by year

Filters applied: . Clear all
Page 1
Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress.
Jiang X, Ma Y, Wang T, Zhou H, Wang K, Shi W, Qin L, Guan J, Li L, Long B, Wang J, Guan X, Ye H, Yang J, Yu Z, Jiao Z. Jiang X, et al. Gastroenterology. 2023 Jun;164(7):1232-1247. doi: 10.1053/j.gastro.2023.02.025. Epub 2023 Feb 25. Gastroenterology. 2023. PMID: 36842710
BACKGROUND & AIMS: Although small patient subsets benefit from current targeted strategies or immunotherapy, gemcitabine remains the first-line drug for pancreatic cancer (PC) treatment. However, gemcitabine resistance is widespread and compromises long-term sur …
BACKGROUND & AIMS: Although small patient subsets benefit from current targeted strategies or immunotherapy, gemcitabine remains …
Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.
Berg T, Nøttrup TJ, Roed H. Berg T, et al. Gynecol Oncol. 2019 Dec;155(3):530-537. doi: 10.1016/j.ygyno.2019.09.026. Epub 2019 Oct 8. Gynecol Oncol. 2019. PMID: 31604664
One study evaluated gemcitabine with gemcitabine and pertuzumab. Overall survival and progression-free survival was similar between the two arms. One study compared gemcitabine and carboplatin to gemcitabine, carboplatin and bevacizumab. Overall surviv …
One study evaluated gemcitabine with gemcitabine and pertuzumab. Overall survival and progression-free survival was similar be …
Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer.
Gu J, Huang W, Wang X, Zhang J, Tao T, Zheng Y, Liu S, Yang J, Chen ZS, Cai CY, Li J, Wang H, Fan Y. Gu J, et al. Mol Cancer. 2022 May 10;21(1):112. doi: 10.1186/s12943-022-01587-9. Mol Cancer. 2022. PMID: 35538494 Free PMC article.
BACKGROUND: Although gemcitabine has been considered as the first-line drug for advanced pancreatic cancer (PC), development of resistance to gemcitabine severely limits the effectiveness of this chemotherapy, and the underlying mechanism of gemcitabine resis …
BACKGROUND: Although gemcitabine has been considered as the first-line drug for advanced pancreatic cancer (PC), development of resis …
Gemcitabine-induced radiation recall.
Jeter MD, Jänne PA, Brooks S, Burstein HJ, Wen P, Fuchs CS, Loeffler JS, Devlin PM, Salgia R. Jeter MD, et al. Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):394-400. doi: 10.1016/s0360-3016(02)02773-6. Int J Radiat Oncol Biol Phys. 2002. PMID: 12023144 Review.
No radiation therapy was given concomitantly with gemcitabine. Treatment of the recall reaction consisted of discontinuing gemcitabine and initiating steroid therapy, supportive therapy, and/or nonsteroidal anti-inflammatory agents. ...Treating physicians must be aw …
No radiation therapy was given concomitantly with gemcitabine. Treatment of the recall reaction consisted of discontinuing gemcita …
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O, Elsayed Z, Elhalawani H. Abdel-Rahman O, et al. Cochrane Database Syst Rev. 2018 Apr 6;4(4):CD011746. doi: 10.1002/14651858.CD011746.pub2. Cochrane Database Syst Rev. 2018. PMID: 29624208 Free PMC article.
OBJECTIVES: To assess the benefits and harms of intravenous administration of gemcitabine monotherapy or gemcitabine-based chemotherapy versus placebo, or no intervention, or other treatments (excluding gemcitabine) in adults with advanced biliary tract carci …
OBJECTIVES: To assess the benefits and harms of intravenous administration of gemcitabine monotherapy or gemcitabine-based che …
Small Molecular Gemcitabine Prodrugs for Cancer Therapy.
Miao H, Chen X, Luan Y. Miao H, et al. Curr Med Chem. 2020;27(33):5562-5582. doi: 10.2174/0929867326666190816230650. Curr Med Chem. 2020. PMID: 31419928 Review.
Gemcitabine as a pyrimidine nucleoside analog anticancer drug has high efficacy for a broad spectrum of solid tumors. ...In the field of medicinal chemistry, prodrugs have proven to be a very effective means for elevating drug stability and decrease undesirable side effect …
Gemcitabine as a pyrimidine nucleoside analog anticancer drug has high efficacy for a broad spectrum of solid tumors. ...In the field …
Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies.
Natu J, Nagaraju GP. Natu J, et al. Cancer Lett. 2023 Oct 1;573:216382. doi: 10.1016/j.canlet.2023.216382. Epub 2023 Sep 2. Cancer Lett. 2023. PMID: 37666293 Review.
In preclinical models, certain schedules of administration of gemcitabine modulate the TME in a manner that does not promote resistance. Metronomic therapy constitutes a promising strategy to overcome some barriers associated with current PDAC treatments. This review will …
In preclinical models, certain schedules of administration of gemcitabine modulate the TME in a manner that does not promote resistan …
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML. Maki RG, et al. J Clin Oncol. 2007 Jul 1;25(19):2755-63. doi: 10.1200/JCO.2006.10.4117. J Clin Oncol. 2007. PMID: 17602081 Clinical Trial.
The adaptive randomization assigned 73 patients (60%) to gemcitabine-docetaxel and 49 patients (40%) to gemcitabine alone, indicating gemcitabine-docetaxel was superior. ...Median progression-free survival was 6.2 months for gemcitabine-docetaxel and 3 …
The adaptive randomization assigned 73 patients (60%) to gemcitabine-docetaxel and 49 patients (40%) to gemcitabine alone, ind …
Gemcitabine-associated hemolytic-uremic syndrome.
Walter RB, Joerger M, Pestalozzi BC. Walter RB, et al. Am J Kidney Dis. 2002 Oct;40(4):E16. doi: 10.1053/ajkd.2002.35758. Am J Kidney Dis. 2002. PMID: 12324937 Review.
BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported. ...Mean time between initiation of gemcitabine therapy and onset of HUS was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of …
BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been …
Preclinical characteristics of gemcitabine.
Plunkett W, Huang P, Gandhi V. Plunkett W, et al. Anticancer Drugs. 1995 Dec;6 Suppl 6:7-13. doi: 10.1097/00001813-199512006-00002. Anticancer Drugs. 1995. PMID: 8718419 Review.
Once inside the cell gemcitabine is rapidly phosphorylated by deoxycytidine kinase, the rate-limiting enzyme for the formation of the active metabolites gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP). ...Other self-potentiating mechani …
Once inside the cell gemcitabine is rapidly phosphorylated by deoxycytidine kinase, the rate-limiting enzyme for the formation of the …
24,188 results
You have reached the last available page of results. Please see the User Guide for more information.